ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Neuroprotective effect of niacin in a rat model of obesity induced by high-fat-rich diet.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Investigating the protective effect of zinc oxide-gallic acid nanoparticles against depression like behavior and memory impairment in animals treated with D-galactose.Scientific reports · 2026Article
- Acipimox as a potential antioxidant and neuromodulator mitigates high fat diet induced cognitive dysfunction.Scientific reports · 2025Article
- Anxiolytic effect of zinc oxide gallic acid composite nanoparticles following D-galactose administration in rats.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study investigates the impact of a high-fat-rich diet (HFRD) on behavioral, biochemical, neurochemical, and histopathological studies using the hypothalamus of rats following niacin (NCN) administration. The rats were divided into HFRD and normal diet (ND)-fed groups and administered selected doses of NCN, i.e., 25 mg/mL/kg (low dose) and 50 mg/mL/kg (high dose), for 8 weeks. The grouping of male rats (n = 8) was as follows: (i) Vehicle (Veh) + ND; (ii) ND + NCN (low dose); (iii) ND + NCN (high dose); (iv) Veh + HFRD; (v) HFRD + NCN (low dose); and (vi) HFRD + NCN (high dose). Behavioral tests assessed depression-like symptoms and spatial memory; after that, the hypothalamus was isolated for various analyses of sacrificed animals. NCN at both doses decreased food intake and growth rate in both diet groups and demonstrated antidepressant and memory-enhancing effects. HFRD-induced oxido-neuroinflammation decreased with both doses of NCN. HFRD-induced decreases in serotonergic neurotransmission, 5-HT1A receptor expression, and morphological alterations in the rat's hypothalamus were normalized by both doses of NCN. In conclusion, NCN, as a potential antioxidant and neuromodulator, can normalize feeding behavior and produce antidepressant and memory-improving effects in a rat model of obesity following HFRD intake.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.